5-(4-Phenoxybutoxy)psoralen

Base Information

• Chemical Name: 5-(4-Phenoxybutoxy)psoralen
• CAS No.: 870653-45-5
• Molecular Formula: C21H18O5
• Molecular Weight: 350.371
• Hs Code.: 2932999099
• European Community (EC) Number: 635-565-8
• UNII: A62C114Q0Q
• ChEMBL ID: CHEMBL444449
• DSSTox Substance ID: DTXSID80461776
• Pharos Ligand ID: YQ6FVSKVMWJJ
• Wikidata: Q27073964
• Mol file: 870653-45-5.mol

Synonyms:5-(4-Phenoxybutoxy)psoralen;870653-45-5;PAP-1;4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one;SPS-4251;4-(4-phenoxybutoxy)furo[3,2-g]chromen-7-one;CHEMBL444449;7H-Furo[3,2-g][1]benzopyran-7-one, 4-(4-phenoxybutoxy)-;A62C114Q0Q;7H-Furo(3,2-g)(1)benzopyran-7-one, 4-(4-phenoxybutoxy)-;4-(4-Phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one;UNII-A62C114Q0Q;5-(4-phenoxybutoxy) psoralen;GTPL2554;SCHEMBL2585454;DTXSID80461776;KINMYBBFQRSVLL-UHFFFAOYSA-N;AS-77;HMS3741O03;BCP07288;EX-A6140;BDBM50279106;AKOS015920200;AC-1703;CS-0299;NCGC00165872-01;AS-30928;HY-10015;FT-0699798;4-[4-(phenoxy)butoxy]furo[3,2-g]chromen-7-one;5-(4-Phenoxybutoxy)psoralen, >=98% (HPLC), solid;Q27073964;4-(4-Phenoxybutoxy)-7H-furo[3,2-g][1]benzopyran-7-on

Chemical Property of 5-(4-Phenoxybutoxy)psoralen

Chemical Property:

• Appearance/Colour: white solid
• Vapor Pressure: 2.17E-12mmHg at 25°C
• Refractive Index: 1.618
• Boiling Point: 555.8 °C at 760 mmHg
• Flash Point: 289.9 °C
• PSA: 61.81000
• Density: 1.269 g/cm³
• LogP: 4.77720
• Storage Temp.: 2-8°C
• Solubility.: DMSO: 9 mg/mL
• XLogP3: 4.7
• Hydrogen Bond Donor Count: 0
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 7
• Exact Mass: 350.11542367
• Heavy Atom Count: 26
• Complexity: 499

Purity/Quality:

98%,99%, ^*data from raw suppliers

5-(4-Phenoxybutoxy)psoralen ≥98% (HPLC), solid ^*data from reagent suppliers

Safty Information:

• Statements: 42/43
• Safety Statements: 22-36/37-45

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C1=CC=C(C=C1)OCCCCOC2=C3C=CC(=O)OC3=CC4=C2C=CO4
• Uses: 5-(4-Phenoxybutoxy)psoralen (CAS# 870653-45-5) is a selective small molecule blocker of the lymphocyte K+ channel Kv1.3 and is used for the suppression of effector memory T cells in autoimmune diseases.

Technology Process of 5-(4-Phenoxybutoxy)psoralen

There total 3 articles about 5-(4-Phenoxybutoxy)psoralen which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 60.5%

bergaptol (486-60-2) + 4-bromophenyl butyl ether (1200-03-9) → PAP-1 (870653-45-5)

Guidance literature:

With potassium carbonate; potassium iodide; In butanone; for 24h; Heating;

DOI:10.1124/mol.105.015669

Reference yield:

bergapten (484-20-8) → PAP-1 (870653-45-5)

Guidance literature:

Multi-step reaction with 2 steps

1: magnesium; iodine / 165 °C

2: 60.5 percent / potassium carbonate; potassium iodide / butan-2-one / 24 h / Heating

With iodine; potassium carbonate; magnesium; potassium iodide; In butanone;

DOI:10.1124/mol.105.015669

Reference yield:

sodium phenoxide (139-02-6) → PAP-1 (870653-45-5)

Guidance literature:

Multi-step reaction with 2 steps

1: ethanol / 4 h / Heating

2: 60.5 percent / potassium carbonate; potassium iodide / butan-2-one / 24 h / Heating

With potassium carbonate; potassium iodide; In ethanol; butanone;

DOI:10.1124/mol.105.015669

upstream raw materials:

bergaptol

4-bromophenyl butyl ether

bergapten

sodium phenoxide

Downstream raw materials:

4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromene-7-thione

Refernces

• 1、 Schmitz, Alexander,Sankaranarayanan, Ananthakrishnan,Azam, Philippe,Schmidt-Lassen, Kristina,Homerick, Daniel,Haensel, Wolfram,Wulff, Heike. "Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory t cells in autoimmune diseases". . p. 1254 - 1270. Retrieved 2007/10/03.